home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

104.91 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

What Has Cathie Wood Been Trading? ↗

April 19, 2023

The story of Ark Invest, Wall Street veteran Cathie Wood’s lineup of actively managed, innovation-centric ETFs is well-known at this point. Ark has been defined by big bets, big wins, big losses, and...

Via Benzinga

2 Supercharged Growth Stocks That Could Rocket 116% to 899% Higher, According to Wall Street ↗

April 15, 2023

Find out why expectations are so high for these two innovative businesses.

Via The Motley Fool

The 3 Best Millionaire-Maker Stocks to Buy for April 2023 ↗

April 07, 2023

These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire.

Via InvestorPlace

3 Cathie Wood Stocks for Your April Must-Buy List ↗

April 04, 2023

Cathie Wood stocks are doing much better in 2023 than last year. Here are three to put on your April must-buy list.

Via InvestorPlace

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle ↗

April 03, 2023

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell.

Via Investor's Business Daily

Analyst Ratings for Exact Sciences ↗

March 03, 2023

Via Benzinga

Canaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To Know ↗

February 22, 2023

Via Benzinga

Earnings Preview For Exact Sciences ↗

February 20, 2023

Via Benzinga

The Latest Analyst Ratings for Exact Sciences ↗

February 10, 2023

Via Benzinga

3 Stocks With Superior Potential for Super-Sized Gains in 2023 ↗

March 22, 2023

Investing in stocks with potential is a great way to make money as long as you do your research and understand the risks involved.

Via InvestorPlace

If You Invested $10,000 in Exact Sciences in 2018, This Is How Much You Would Have Today ↗

March 16, 2023

Has this been a market-beating investment?

Via The Motley Fool

EXAS Stock Is a Hidden Gem in the Healthcare Sector for Bold Investors ↗

March 16, 2023

Patient investors who have room for an intriguing medical-niche investment in their portfolio should take a closer look at EXAS stock.

Via InvestorPlace

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

March 15, 2023

Credit Suisse cut the price target for Zscaler, Inc. (NASDAQ: ZS) from $275 to $165. Credit Suisse analyst Sami Badri maintained an Outperform rating. Zscaler shares fell 1.9% to $105.95 in pre-market...

Via Benzinga

7 Growth Stocks Sitting in a Sweet Spot ↗

March 14, 2023

Offering ample growth potential, and each attractively-priced, now's the time to buy these seven growth stocks.

Via InvestorPlace

A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold ↗

March 12, 2023

It pays to be an innovator.

Via The Motley Fool

What You Missed On Wall Street On Thursday ↗

March 09, 2023

SVB Financial is lower after the company announced it was undertaking a strategic repositioning of its balance sheet and also provided a negative update to both Q1 and full-year 2023 guidance.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

Cathie Wood Is Betting Big on These 5 AI Stocks ↗

March 01, 2023

Investors are betting on Cathie Wood again thanks to growing AI stocks interest. Wood's Ark Invest holds several compelling AI picks.

Via InvestorPlace

Exact Sciences (EXAS) Q4 2022 Earnings Call Transcript ↗

February 21, 2023

EXAS earnings call for the period ending December 31, 2022.

Via The Motley Fool

After-Hours Action: What's Going On With Exact Sciences Stock? ↗

February 21, 2023

Exact Sciences Corp (NASDAQ: EXAS) shares are facing selling pressure after the close on Tuesday on the heels of the company's quarterly results.

Via Benzinga

Exact Sciences, Which Outperforms 95% Of All Stocks, Just Beat Quarterly Estimates ↗

February 21, 2023

Exact Sciences is leaned on Cologuard for strong fourth-quarter sales growth.

Via Investor's Business Daily

Cathie Wood Bulks Up On Shopify Amid Stock's 18% Post-Earnings Drop, Sells This Major Holding Up 30% This Week ↗

February 18, 2023

Cathie Wood’s Ark Invest reversed its stance on Canadian e-commerce retailer Shopify, Inc. (NYSE: SHOP) and began bulking up on the stock this week.

Via Benzinga

25 AI Stocks to Buy Right Now ↗

February 16, 2023

Looking to benefit from the AI boom started by ChatGPT? Here are the best AI stocks to buy for the emerging market frenzy.

Via InvestorPlace

Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023? ↗

February 16, 2023

Which of these rebounding biotech stocks is the better buy right now?

Via The Motley Fool

3 Growth Stocks That Are Off to Hot Starts in 2023 ↗

February 08, 2023

Are these stocks still good buys right now?

Via The Motley Fool

7 AI Penny Stocks to Watch as a New Bull Market Emerges ↗

February 07, 2023

Looking to profit off the current AI boom? Here are the most important AI penny stocks for investors to be watching.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023 ↗

February 10, 2023

Via Benzinga

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Via MarketBeat

Topics ETFs

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com